- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-BMR1B/ BMPR1B/ ALK-6 monoclonal antibody
Anti-BMR1B/ BMPR1B/ ALK-6 antibody for FACS & in-vivo assay
Go to BMPR1B/BMPR1B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP0137-Ab-1/ GM-Tg-hg-MP0137-Ab-2 | Anti-Human BMPR1B monoclonal antibody | Human |
| GM-Tg-rg-MP0137-Ab-1/ GM-Tg-rg-MP0137-Ab-2 | Anti-Rat BMPR1B monoclonal antibody | Rat |
| GM-Tg-mg-MP0137-Ab-1/ GM-Tg-mg-MP0137-Ab-2 | Anti-Mouse BMPR1B monoclonal antibody | Mouse |
| GM-Tg-cynog-MP0137-Ab-1/ GM-Tg-cynog-MP0137-Ab-2 | Anti-Cynomolgus/ Rhesus macaque BMPR1B monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP0137-Ab-1/ GM-Tg-felg-MP0137-Ab-2 | Anti-Feline BMPR1B monoclonal antibody | Feline |
| GM-Tg-cang-MP0137-Ab-1/ GM-Tg-cang-MP0137-Ab-2 | Anti-Canine BMPR1B monoclonal antibody | Canine |
| GM-Tg-bovg-MP0137-Ab-1/ GM-Tg-bovg-MP0137-Ab-2 | Anti-Bovine BMPR1B monoclonal antibody | Bovine |
| GM-Tg-equg-MP0137-Ab-1/ GM-Tg-equg-MP0137-Ab-2 | Anti-Equine BMPR1B monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP0137-Ab-1/ GM-Tg-hg-MP0137-Ab-2; GM-Tg-rg-MP0137-Ab-1/ GM-Tg-rg-MP0137-Ab-2; GM-Tg-mg-MP0137-Ab-1/ GM-Tg-mg-MP0137-Ab-2; GM-Tg-cynog-MP0137-Ab-1/ GM-Tg-cynog-MP0137-Ab-2; GM-Tg-felg-MP0137-Ab-1/ GM-Tg-felg-MP0137-Ab-2; GM-Tg-cang-MP0137-Ab-1/ GM-Tg-cang-MP0137-Ab-2; GM-Tg-bovg-MP0137-Ab-1/ GM-Tg-bovg-MP0137-Ab-2; GM-Tg-equg-MP0137-Ab-1/ GM-Tg-equg-MP0137-Ab-2 |
| Products Name | Anti-BMPR1B monoclonal antibody |
| Format | mab |
| Target Name | BMPR1B |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-BMPR1B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species BMR1B/ BMPR1B/ ALK-6 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-MP0137-Ag-1 | bone morphogenetic protein receptor, type IB (BMPR1B) protein |
| ORF Viral Vector | pGMLPm002522 | mouse Bmpr1b Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002522 | mouse Bmpr1b Lentivirus particle |
Target information
| Target ID | GM-MP0137 |
| Target Name | BMPR1B |
| Gene ID | 658,12167,310914,705474,478484,101082489,407128,100053554 |
| Gene Symbol and Synonyms | Acvrlk6,ALK-6,ALK6,AMD3,AMDD,BDA1D,BDA2,BMP15,BMPR-1B,BMPR-IB,BMPR1B,BMPRIB,CDw293,CFK-43a,SKR6 |
| Uniprot Accession | O00238 |
| Uniprot Entry Name | BMR1B_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Cytokine Target |
| Disease | N/A |
| Gene Ensembl | ENSG00000138696 |
| Target Classification | Kinase |
The target: BMPR1B, gene name: BMPR1B, also named as ALK-6, ALK6, AMDD, BDA1D, BDA2, CDw293. This gene encodes a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in this gene have been associated with primary pulmonary hypertension. Several transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Feb 2012].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
